Influence of vitamin D treatment on functional expression of drug disposition pathways in human kidney proximal tubule cells during simulated uremia

References

• Aiba, T., et al., 2005. The effects of culture conditions on CYP3A4 and MDR1 mRNA induction by 1α, 25-dihydroxyvitamin D3 in human intestinal cell lines, Caco-2 and LS180. Drug metabolism and pharmacokinetics, 20 (4), 268–274.
   PubMedGoogle Scholar
• Baker, A.R., et al., 1988. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proceedings of the national academy of sciences of the United States of America, 85 (10), 3294–3298.
   PubMed Web of Science ®Google Scholar
• Baldi, P., and Long, A.D., 2001. A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes. Bioinformatics, 17 (6), 509–519.
   PubMed Web of Science ®Google Scholar
• Berger, U., et al., 1988. Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. The journal of clinical endocrinology and metabolism, 67 (3), 607–613.
   PubMed Web of Science ®Google Scholar
• Bhan, I., et al., 2010. Clinical measures identify vitamin D deficiency in dialysis. Clinical journal of the American society of nephrology, 5 (3), 460–467.
   PubMed Web of Science ®Google Scholar
• Blomberg Jensen, M., et al., 2010. Expression of the vitamin D receptor, 25-hydroxylases, 1alpha-hydroxylase and 24-hydroxylase in the human kidney and renal clear cell cancer. The journal of steroid biochemistry and molecular biology, 121 (1-2), 376–382.
   PubMed Web of Science ®Google Scholar
• Bossé, Y., Maghni, K., and Hudson, T.J., 2007. 1α, 25-Dihydroxy-vitamin D3 stimulation of bronchial smooth muscle cells induces autocrine, contractility, and remodeling processes. Physiological genomics, 29 (2), 161–168.
   PubMed Web of Science ®Google Scholar
• Cheng, S., and Coyne, D., 2007. Vitamin D and outcomes in chronic kidney disease. Current opinion in nephrology and hypertension, 16 (2), 77–82.
   PubMed Web of Science ®Google Scholar
• Chow, E.C., et al., 2011. Comparative effects of doxercalciferol (1alpha-hydroxyvitamin D(2)) versus calcitriol (1alpha,25-dihydroxyvitamin D(3)) on the expression of transporters and enzymes in the rat in vivo. Journal of pharmaceutical sciences., 100 (4), 1594–1604.
   PubMedGoogle Scholar
• Chow, E.C., et al., 2010. Effects of 1alpha,25-dihydroxyvitamin D3 on transporters and enzymes of the rat intestine and kidney in vivo. Biopharmaceutics & drug disposition, 31 (1), 91–108.
   PubMed Web of Science ®Google Scholar
• Coresh, J., et al., 2007. Prevalence of chronic kidney disease in the United States. Jama, 298 (17), 2038–2047.
   PubMed Web of Science ®Google Scholar
• Cvetkovic, M., et al., 1999. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug metabolism and disposition: the biological fate of chemicals, 27 (8), 866–871.
   PubMed Web of Science ®Google Scholar
• Deeb, K.K., Trump, D.L., and Johnson, C.S., 2007. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nature reviews. cancer, 7 (9), 684–700.
   PubMed Web of Science ®Google Scholar
• Fan, J., et al., 2009a. Up-regulation of transporters and enzymes by the vitamin D receptor ligands, 1alpha,25-dihydroxyvitamin D3 and vitamin D analogs, in the Caco-2 cell monolayer. Journal of pharmacology and experimental therapeutics, 330 (2), 389–402.
   PubMed Web of Science ®Google Scholar
• Fan, J., et al., 2009b. Up-regulation of transporters and enzymes by the vitamin D receptor ligands, 1α, 25-dihydroxyvitamin D3 and vitamin D analogs, in the Caco-2 cell monolayer. Journal of pharmacology and experimental therapeutics, 330 (2), 389–402.
   PubMed Web of Science ®Google Scholar
• Fenner, K.S., et al., 2009. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clinical pharmacology & therapeutics, 85 (2), 173–181.
   PubMed Web of Science ®Google Scholar
• Fischer, D., et al., 2009. Vitamin D-24-hydroxylase in benign and malignant breast tissue and cell lines. Anticancer research, 29 (9), 3641–3645.
   PubMed Web of Science ®Google Scholar
• Gedeon, T., and Bokes, P., 2012. Delayed protein synthesis reduces the correlation between mRNA and protein fluctuations. Biophysical journal, 103 (3), 377–385.
   PubMed Web of Science ®Google Scholar
• González, E.A., et al., 2004. Vitamin D insufficiency and deficiency in chronic kidney disease. American journal of nephrology, 24 (5), 503–510.
   PubMed Web of Science ®Google Scholar
• Greenbaum, D., et al., 2003. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome biology, 4 (9), 117.
   PubMed Web of Science ®Google Scholar
• Heaney, R.P., 2008. Vitamin D in health and disease. Clinical journal of the American society of nephrology, 3 (5), 1535–1541.
   PubMed Web of Science ®Google Scholar
• Helvig, C.F., et al., 2010. Dysregulation of renal vitamin D metabolism in the uremic rat. Kidney international, 78 (5), 463–472.
   PubMed Web of Science ®Google Scholar
• Hirata, M., et al., 2002. 22-Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats. Nephrology, dialysis, transplantation, 17 (12), 2132–2137.
   PubMed Web of Science ®Google Scholar
• Holick, M.F., 2007. Vitamin D deficiency. New England journal of medicine, 357 (3), 266–281.
   PubMed Web of Science ®Google Scholar
• Holick, M.F., et al.,; Endocrine Society. 2011. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. The journal of clinical endocrinology and metabolism, 96 (7), 1911–1930.
   PubMed Web of Science ®Google Scholar
• Horvath, E., et al., 2012. Marked increase of CYP24A1 mRNA level in hepatocellular carcinoma cell lines following vitamin D administration. Anticancer research, 32, 4791–4796.
   PubMed Web of Science ®Google Scholar
• Jones, G., 2007. Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D(3). Seminars in dialysis, 20 (4), 316–324.
   PubMed Web of Science ®Google Scholar
• Jones, G., Strugnell, S.A., and Deluca, H.F., 1998. Current understanding of the molecular actions of vitamin D. Physiological reviews, 78 (4), 1193–1231.
   PubMed Web of Science ®Google Scholar
• Kandula, P., et al., 2011. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clinical journal of the american society of nephrology, 6 (1), 50–62.
   PubMed Web of Science ®Google Scholar
• Karyekar, C.S., et al., 2004. Renal interaction between itraconazole and cimetidine. The Journal of Clinical Pharmacology, 44 (8), 919–927.
   PubMed Web of Science ®Google Scholar
• Kawakami, T., et al., 2010. Indoxyl sulfate inhibits proliferation of human proximal tubular cells via endoplasmic reticulum stress. American journal of physiology. Renal physiology, 299 (3), F568–F576.
   PubMed Web of Science ®Google Scholar
• Li, Y.C., 2010. Renoprotective effects of vitamin D analogs. Kidney international, 78 (2), 134–139.
   PubMed Web of Science ®Google Scholar
• Livak, K.J., and Schmittgen, T.D., 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25 (4), 402–408.
   PubMed Web of Science ®Google Scholar
• Maeng, H.J., et al., 2012. Effects of 1α,25-dihydroxyvitamin D3 on transport and metabolism of adefovir dipivoxil and its metabolites in Caco-2 cells . European journal of pharmaceutical sciences, 46 (3), 149–166.
   PubMed Web of Science ®Google Scholar
• Manley, H.J., Drayer, D.K., and Muther, R.S., 2003. Medication-related problem type and appearance rate in ambulatory hemodialysis patients. BMC nephrology, 4, 10.
   PubMedGoogle Scholar
• Massry, S.G., et al., 2003. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. American journal of kidney diseases, 42, S1–S201.
   PubMed Web of Science ®Google Scholar
• Mehrotra, R., et al., 2008. Hypovitaminosis D in chronic kidney disease. Clinical journal of the american society of nephrology, 3 (4), 1144–1151.
   PubMed Web of Science ®Google Scholar
• Mehrotra, R., et al., 2009. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney international, 76 (9), 977–983.
   PubMed Web of Science ®Google Scholar
• Mehrotra, R., et al.,; on behalf of the Kidney Early Evaluation Program (KEEP) Investigators. 2013. No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease. Kidney International, 84 (5), 989–997.
   PubMed Web of Science ®Google Scholar
• Melaine, N., et al., 2002. Multidrug resistance genes and p-glycoprotein in the testis of the rat, mouse, Guinea pig, and human. Biology of Reproduction, 67 (6), 1699–1707.
   PubMed Web of Science ®Google Scholar
• Michaud, J., et al., 2005. Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. British journal of pharmacology, 144 (8), 1067–1077.
   PubMed Web of Science ®Google Scholar
• Michaud, J., et al., 2010. Reduced hepatic synthesis of calcidiol in uremia. Journal of the American society of nephrology, 21 (9), 1488–1497.
   PubMed Web of Science ®Google Scholar
• Michaud, J., et al., 2008. Effect of hemodialysis on hepatic cytochrome P450 functional expression. Journal of pharmacological sciences, 108 (2), 157–163.
   PubMed Web of Science ®Google Scholar
• Mikkaichi, T., et al., 2004a. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proceedings of the national Academy of sciences, 101, 3569–3574.
   PubMed Web of Science ®Google Scholar
• Mikkaichi, T., et al., 2004b. The organic anion transporter (OATP) family. Drug metabolism and pharmacokinetics, 19 (3), 171–179.
   PubMedGoogle Scholar
• Morrissey, K.M., et al., 2013. Renal transporters in drug development. Annual review of pharmacology and toxicology, 53, 503–529.
   PubMed Web of Science ®Google Scholar
• Mozar, A., et al., 2011. Uremic toxin indoxyl sulfate inhibits human vascular smooth muscle cell proliferation. Therapeutic apheresis and dialysis, 15 (2), 135–139.
   PubMed Web of Science ®Google Scholar
• Narbaitz, R., Stumpf, W.E., and Sar, M., 1981. The role of autoradiographic and immunocytochemical techniques in the clarification of sites of metabolism and action of vitamin D. The journal of histochemistry and cytochemistry, 29 (1), 91–100.
   PubMed Web of Science ®Google Scholar
• Naud, J., et al., 2011. Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats. Drug metabolism and disposition, 39 (8), 1363–1369.
   PubMed Web of Science ®Google Scholar
• Naud, J., et al., 2008. Effects of chronic renal failure on liver drug transporters. Drug metabolism and disposition, 36 (1), 124–128.
   PubMed Web of Science ®Google Scholar
• Nolin, T., et al., 2008. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clinical pharmacology and therapeutics, 83 (6), 898–903.
   PubMed Web of Science ®Google Scholar
• Ozerkan, D., Ozsoy, N., and Yilmaz, E., 2015. Vitamin D and melatonin protect the cell's viability and ameliorate the CCl4 induced cytotoxicity in HepG2 and Hep3B hepatoma cell lines. Cytotechnology, 67, 995–1002.
   PubMed Web of Science ®Google Scholar
• Pan, L., et al., 2017. Antiproliferation effect of the uremic toxin para‑cresol on endothelial progenitor cells is related to its antioxidant activity. Molecular medicine reports, 15 (4), 2308–2312.
   PubMed Web of Science ®Google Scholar
• Pramyothin, P., and Holick, M.F., 2012. Vitamin D supplementation: guidelines and evidence for subclinical deficiency. Current opinion in gastroenterology, 28 (2), 139–150.
   PubMed Web of Science ®Google Scholar
• Saeki, M., et al., 2008. Identification of the functional vitamin D response elements in the human MDR1 gene. Biochemical pharmacology, 76 (4), 531–542.
   PubMed Web of Science ®Google Scholar
• Sato, T., et al., 2017. Potential drug interactions mediated by renal organic anion transporter OATP4C1. Journal of pharmacology and experimental therapeutics, 362 (2), 271–277.
   PubMed Web of Science ®Google Scholar
• Schwarz, U., et al., 1998. Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney international, 53 (6), 1696–1705.
   PubMed Web of Science ®Google Scholar
• Steenbergen, R., et al., 2018. Establishing normal metabolism and differentiation in hepatocellular carcinoma cells by culturing in adult human serum. Scientific reports, 8 (1), 11685.
   PubMedGoogle Scholar
• Stumpf, W.E., et al., 1979. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science, 206 (4423), 1188–1190.
   PubMed Web of Science ®Google Scholar
• Sun, H., et al., 2004. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug metabolism and disposition, 32 (11), 1239–1246.
   PubMed Web of Science ®Google Scholar
• Szallasi, Z., 1999. Genetic network analysis in light of massively parallel biological data acquisition. Pacific Symposium on Biocomputing, 4, 5–16.
   PubMedGoogle Scholar
• Tachibana, S., et al., 2009. Involvement of vitamin D receptor in the intestinal induction of human ABCB1. Drug metabolism and disposition, 37 (8), 1604–1610.
   PubMed Web of Science ®Google Scholar
• Tan, X., Wen, X., and Liu, Y., 2008. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. Journal of the American society of nephrology, 19 (9), 1741–1752.
   PubMed Web of Science ®Google Scholar
• Taub, M.E., et al., 2011. Digoxin is not a substrate for organic anion-transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium-dependent transporter expressed in HEK293 cells. Drug metabolism and disposition, 39 (11), 2093–2102.
   PubMed Web of Science ®Google Scholar
• Thomas, M.K., et al., 1998. Hypovitaminosis D in medical inpatients. New England journal of medicine, 338 (12), 777–783.
   PubMed Web of Science ®Google Scholar
• Tohari, A.M., Zhou, X., and Shu, X., 2016. Protection against oxidative stress by vitamin D in cone cells. Cell Biochemistry and Function, 34 (2), 82–94.
   PubMed Web of Science ®Google Scholar
• Tucker, G., 3rd, Gagnon, R.E., and Haussler, M.R., 1973. Vitamin D 3 -25-hydroxylase: tissue occurrence and apparent lack of regulation. Archives of biochemistry and biophysics, 155 (1), 47–57.
   PubMed Web of Science ®Google Scholar
• Ueda, K., et al., 1992. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. Journal of biological chemistry., 267 (34), 24248–24252.
   PubMed Web of Science ®Google Scholar
• Urbschat, A., et al., 2013. Vitamin D hydroxylases CYP2R1, CYP27B1 and CYP24A1 in renal cell carcinoma. European journal of clinical investigation, 43 (12), 1282–1290.
   PubMed Web of Science ®Google Scholar
• Volpe, D.A., et al., 2014. Effect of uremic serum and uremic toxins on drug metabolism in human microsomes. Regulatory toxicology and pharmacology, 68 (2), 297–303.
   PubMed Web of Science ®Google Scholar
• Zhang, L., et al., 2009. Predicting drug-drug interactions: an FDA perspective. The AAPS journal, 11 (2), 300–306.
   PubMed Web of Science ®Google Scholar
• Zhang, Z., et al., 2008. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney international, 73 (2), 163–171.
   PubMed Web of Science ®Google Scholar
• Zierold, C., Mings, J.A., and Deluca, H.F., 2001. Parathyroid hormone regulates 25-hydroxyvitamin D(3)-24-hydroxylase mRNA by altering its stability. Proceedings of the national academy of sciences of the United States of America, 98 (24), 13572–13576.
   PubMed Web of Science ®Google Scholar